Taşçı Cengiz, Ozçelik Nihat
Gama Medical Center, Derpartment of Nuclear Medicine, Gaziantep, Turkey.
Mol Imaging Radionucl Ther. 2011 Dec;20(3):75-93. doi: 10.4274/MIRT.33. Epub 2011 Dec 1.
Coronary heart disease (CHD) is the leading cause of death for men and women in Turkey as it is in Europe and US. The prevalence of the disease is 3.8% in Turkey and 200,000 patients are added to the pool of CHD annually Because of genetic predisposition and high proportions of physical inactivity, smoking habit, and obesity, CHD is encountered in earlier ages in our country So, the economic burden of the disease is expected to be relatively high, but the amount of health expenditure is not always parallel to the prevalence of a disease in the community. This article was written to overview CHD statistics to make a comparison between Turkey and some European countries and to investigate the value of myocardial perfusion scan (MPS) as a gatekeeper in diagnosing CHD before invasive coronary angiography (ICA). The consequences were evaluated for Turkey In diagnosis; noninvasive testing gains importance in connection with the new approaches in treatment strategies, because a direct ICA strategy results in higher rates of revascularization without improvement in clinical outcomes. A "gatekeeper" is needed to select the patients who are not required to undergo angiography. MPS with its proved power in diagnosis and predicting prognosis, provides a cost-effective solution, and is accepted in some extensive analyses as a "gatekeeper" particularly in intermediate and high risk patients and in patients with known CHD. In conclusion, MPS may provide an optimal solution better than the ongoing situation in Turkey as well, when it is approved as a "gatekeeper in an algorithm before ICA.
None declared.
冠心病（CHD）是土耳其男性和女性的主要死因，在欧洲和美国亦是如此。土耳其该病的患病率为3.8%，每年有20万患者加入冠心病患者群体。由于遗传易感性以及缺乏运动、吸烟习惯和肥胖比例较高，我国冠心病发病年龄较早。因此，预计该病的经济负担相对较高，但卫生支出数额并不总是与社区疾病患病率平行。撰写本文旨在概述冠心病统计数据，比较土耳其与一些欧洲国家的情况，并研究心肌灌注扫描（MPS）作为侵入性冠状动脉造影（ICA）前诊断冠心病的“守门人”的价值。对土耳其的结果进行了评估。在诊断方面；随着治疗策略的新方法出现，非侵入性检测变得愈发重要，因为直接进行ICA策略会导致血管重建率更高，但临床结果并无改善。需要一个“守门人”来挑选无需进行血管造影的患者。MPS在诊断和预测预后方面具有已证实的能力，提供了一种具有成本效益的解决方案，并且在一些广泛分析中被接受为“守门人”，特别是在中高危患者和已知冠心病患者中。总之，当MPS被批准作为ICA前算法中的“守门人”时，它可能也会比土耳其目前的情况提供一个更好的最佳解决方案。
未声明。
